Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors

Am J Cardiol. 2002 Apr 15;89(8):976-9. doi: 10.1016/s0002-9149(02)02251-8.

Authors

Ioannis Iakovou¹, George Dangas, Roxana Mehran, Alexandra J Lansky, Yoshio Kobayashi, Milena Adamian, Sotir Polena, Micheal B Collins, Gary S Roubin, Gregg W Stone, Martin B Leon, Jeffrey W Moses

Affiliation

¹ Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, New York 10022, USA.

PMID: 11950440
DOI: 10.1016/s0002-9149(02)02251-8

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Abciximab
Aged
Antibodies, Monoclonal / therapeutic use
Cardiac Catheterization
Coronary Disease / epidemiology
Coronary Disease / therapy*
Eptifibatide
Female
Humans
Immunoglobulin Fab Fragments / therapeutic use
Male
Middle Aged
Peptides / therapeutic use
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Sex Factors
Stents*
Tirofiban
Treatment Outcome
Tyrosine / analogs & derivatives*
Tyrosine / therapeutic use

Substances

Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Peptides
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Tyrosine
Tirofiban
Eptifibatide
Abciximab